# EDGAR Filing Document

**Accession Number:** 0001858685
**File Stem:** 0001493152-26-029079
**Filing Date:** 2026-6
**Character Count:** 6374
**Document Hash:** cce3ce07135035711813abae8ed768fb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-029079.hdr.sgml**: 20260617

**ACCESSION NUMBER**: 0001493152-26-029079

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260611

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260617

**DATE AS OF CHANGE**: 20260617

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Biofrontera Inc.
- **CENTRAL INDEX KEY:** 0001858685
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 473765675
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40943
- **FILM NUMBER:** 261098317

**BUSINESS ADDRESS:**
- **STREET 1:** 120 PRESIDENTIAL WAY,
- **STREET 2:** SUITE 330
- **CITY:** WOBURN
- **STATE:** MA
- **ZIP:** 01801
- **BUSINESS PHONE:** 781-245-1325

**MAIL ADDRESS:**
- **STREET 1:** 120 PRESIDENTIAL WAY,
- **STREET 2:** SUITE 330
- **CITY:** WOBURN
- **STATE:** MA
- **ZIP:** 01801

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): June 11, 2026**

**Biofrontera Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40943** | **47-3765675** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **660 Main Street** **, 1st Floor**<br> **Woburn, Massachusetts** | **01801** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (781) 245-1325**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common stock, par value $0.001 per share** | **BFRI** | **The Nasdaq Stock Market LLC** |
| **Warrants to purchase common stock** | **BFRIW** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (the "Exchange Act") (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.07 Submission of Matters to a Vote of Security Holders**

On June 11, 2026, Biofrontera Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). Proxies for the Annual Meeting were solicited pursuant to Regulation 14A under the Securities Exchange Act of 1934, and there was no solicitation in opposition to the Company's solicitation. Details of the proposals voted on at the Annual Meeting are described in the Proxy Statement filed by the Company with the Securities and Exchange Commission on April 30, 2026. There were present at the Annual Meeting holders of shares representing 11,630,133 votes, constituting a quorum. The following summarizes all matters voted on at the Annual Meeting.

1. Stockholders elected Beth J. Hoffman, Ph.D. and Kevin D. Weber to serve as Class II directors of the Company until the 2029 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal. The tabulation of votes cast was as follows:

**Beth J. Hoffman, Ph.D.**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **For** | **Withheld** | **Withheld** | **Broker Non-Votes** | **Broker Non-Votes** |
| 8089416 |  | 221060 |  | 3319657 |

---

**Kevin D. Weber**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **For** | **Withheld** | **Withheld** | **Broker Non-Votes** | **Broker Non-Votes** |
| 8203433 |  | 107043 |  | 3319657 |

---

2. Stockholders approved the amendment and restatement of the Company's 2021 Omnibus Incentive Plan, including to increase the total number of shares of common stock authorized thereunder from 3,750,000 to 8,750,000. The tabulation of votes cast was as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **For** | **Against** | **Against** | **Abstain** | **Abstain** | **Broker Non-Votes** | **Broker Non-Votes** |
| 7893236 |  | 241359 |  | 175881 |  | 3319657 |

---

3. Stockholders ratified the appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The tabulation of votes cast was as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **For** | **Against** | **Against** | **Abstain** | **Abstain** | **Broker Non-Votes** | **Broker Non-Votes** |
| 10905016 |  | 723806 |  | 1311 |  | 0 |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **June 17, 2026** | **Biofrontera Inc.** |
| (Date) | (Registrant) |
|  | */s/ E. Fred Leffler III* |
|  | E. Fred Leffler III |
|  | *Chief Financial Officer* |

---